Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222986 | 0.89 | KMT2A (0.45) | CHRNA7GAAALDH1A1GHSRSMN1; SMN2 | |
| SCHEMBL2225818 | 0.85 | EPHX2 (0.43) | EPHX2GAAALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL2227483 | 0.84 | EGLN1 (0.42) | EPHX2CHRNA7GAACNR1CNR2 | |
| Hydrochloric Acid SCHEMBL16087367 | 0.83 | EGLN1 (0.42) | EPHX2CHRNA7GAACNR1CNR2 | |
| SCHEMBL2226510 | 0.80 | GHSR (0.47) | SCN9ACHRNA7GHSRSMN1; SMN2HTT | |
| SCHEMBL2226330 | 0.80 | KMT2A (0.40) | CHRNA7GAAGHSRSMN1; SMN2PKM | |
| SCHEMBL6879904 | 0.77 | CHRNA7 (0.39) | CHRNA7GHSRPDE2AHTT | |
| SCHEMBL2226130 | 0.77 | ACACA (0.46) | CHRNA7GHSR | |
| SCHEMBL2226502 | 0.75 | GAA (0.45) | CHRNA7GAAGHSRSMN1; SMN2PKM | |
| Hydrochloric Acid SCHEMBL16087188 | 0.74 | GAA (0.45) | CHRNA7GAAGHSRSMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | claimed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| EP-2533782-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011086377-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CACNA1B, CACNB2, CACNA1C | EPHX2 3815/4885SCN5A 76/4885SCN9A 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.